ASTH
Astrana Health, Inc. (ASTH) ESG Analysis Analysis (2026)
Overall Score
Environmental
No material environmental disclosures or controversies were provided in the fresh data.
The company’s low capex intensity (capexToRevenueTTM 0.45%) suggests limited near-term environmental investment visibility.
Social
No material social disclosures or controversies were provided in the fresh data.
Profitability remains modest (netProfitMarginTTM 1.05%), which limits evidence of strong social investment capacity.
Governance
No material governance disclosures or controversies were provided in the fresh data.
Leverage remains meaningful (debtToEquityRatioTTM 1.18, netDebtToEBITDATTM 3.31), keeping governance/financial discipline relevant.
Risk
No material ESG-specific risks or controversies were reported in recent news.
Interest coverage is thin (interestCoverageRatioTTM 1.49), which can constrain flexibility if operating conditions weaken.
Opportunity
Strong free cash flow conversion (freeCashFlowOperatingCashFlowRatioTTM 90.1%) supports potential for future sustainability or governance investments.
Low price-to-sales (0.48x) and solid cash generation may provide room for incremental ESG-related spending without immediate balance-sheet stress.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Astrana Health, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.